Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus [0.03%]
对比心力衰竭失代偿期合并2型糖尿病患者加用卡格列净、达格列净和恩格列净的疗效
Masaki Nakagaito,Shuji Joho,Ryuichi Ushijima et al.
Masaki Nakagaito et al.
Background: Three sodium-glucose cotransporter-2 inhibitors (SGLT2i), canagliflozin, dapagliflozin and empagliflozin, successfully reduced hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). It remains u...
Potential Role of Twitter at an Annual Congress in Japan - Narrative Literature Review of "Tweet the Meeting" [0.03%]
日本年度大会中使用Twitter的潜在作用——“会议推文”的叙事文献回顾
Atsushi Mizuno,Takuya Kishi,Chisa Matsumoto et al.
Atsushi Mizuno et al.
Background: Twitter has become increasingly popular at annual medical congresses as a platform to communicate to attendees. In contrast, Twitter is not as frequently used in Japan as compared with other countries. Herein, we reviewed the li...
Ningyan Wong,Khung Keong Yeo
Ningyan Wong
In the United States and Europe, percutaneous edge-to-edge repair of the mitral valve with the MitraClip device for patients with severe degenerative mitral regurgitation who are at prohibitive surgical risk has been well-established. Recen...
Severely Impaired Leaflet Mobility of the Tricuspid Valve in an Elderly Woman [0.03%]
老年女性三尖瓣重度瓣叶活动受限
Tatsuro Hitsumoto,Takuya Hasegawa,Yasuhiro Hamatani et al.
Tatsuro Hitsumoto et al.
Addition of Tolvaptan Compared With Increased Dose of Furosemide in Heart Failure Patients With Chronic Kidney Disease Under Furosemide Treatment [0.03%]
与增加呋塞米剂量相比，托伐普坦用于接受呋塞米治疗的慢性肾脏病心力衰竭患者的效果研究
Toshiki Tanaka,Shingo Minatoguchi,Yoshihisa Yamada et al.
Toshiki Tanaka et al.
Background: Given that residual congestion is a predictor of poor outcome in patients with heart failure (HF), a therapeutic strategy for decongestion is required. Methods and Results: Eighteen HF patients with fluid retention despite ora...
Japan Heart Failure Model - Derivation and Accuracy of Survival Prediction in Japanese Heart Failure Patients [0.03%]
日本心力衰竭模型-日本心力衰竭患者生存预测的推导和准确性
Shigeru Miyagawa,Kyongsun Pak,Shungo Hikoso et al.
Shigeru Miyagawa et al.
Background: Accurate prognosis for heart failure (HF) survival is important for quality of life, treatment decisions, and early evaluation of new therapies and devices. Here, we developed a multivariate risk model for predicting survival i...
Low Activities of Daily Living Associated With Increased Cardiovascular Disease Mortality in Japan - Analysis of Health Records From a Nationwide Claim-Based Database, JROAD-DPC [0.03%]
日本JROAD-DPC全国索赔数据库健康记录的心血管疾病死亡率分析：与日常活动能力降低有关
Masaomi Gohbara,Kunihiro Nishimura,Michikazu Nakai et al.
Masaomi Gohbara et al.
Background: The aim of this study was to clarify the clinical impact of activities of daily living (ADL) using the Japanese Registry of All Cardiac and Vascular Diseases-Diagnosis Procedure Combination (JROAD-DPC) database. Methods and Res...
Cardiac Rehabilitation With Dynamic Exercise Increases the Number of Muse Cells in the Peripheral Blood of Patients With Heart Disease [0.03%]
动态运动心脏康复可增加心脏病患者外周血中的多能祖细胞数量
Shingo Minatoguchi,Takahiro Ando,Toshiki Tanaka et al.
Shingo Minatoguchi et al.
Background: It is still unclear whether dynamic exercise increases the number of Muse cells, pluripotent stem cells, in the peripheral blood. Methods and Results: The number of Muse cells, SSEA3+ and CD105+ double-positive cells, in the p...
Heart Failure With Preserved Ejection Fraction - Time for a Paradigm Shift Beyond Diastolic Function [0.03%]
射血分数保留的心力衰竭——超越舒张功能的范式转换时刻
Takashi Oki,Hirokazu Miyoshi,Yoshifumi Oishi et al.
Takashi Oki et al.
At present, heart failure with preserved ejection fraction (HFpEF) is a commonly accepted condition in HF patients. In contrast to HF with reduced EF (HFrEF), HFpEF is strongly associated with aging, and vascular, metabolic, neurohormonal, ...
Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study [0.03%]
对CARMELINA研究的反馈：糖尿病药物与心力衰竭的关系
Motoaki Sano
Motoaki Sano
According to cardiovascular outcome trials, some anti-diabetic drugs can improve cardiovascular outcomes in patients with type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) have a st...